Combined company to be Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Tectonic’s novel GPCR-targeted therapeutic proteins $130.7 million in private financing commitments with new and existing leading life sciences investors in connection with merger Combined company expected to have approximately $165 million in cash and cash equivalents at close to provide cash runway into mid-2027 Funding is... Read More

CAMBRIDGE, Mass. / Jul 12, 2023 / Business Wire / AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities. AVROBIO has made the determination to halt further development of its programs and to conduct a comprehensive... Read More

All-cash transaction, full $87.5 million paid at closing Proceeds expected to extend cash runway into Q4 2024 CAMBRIDGE, Mass. / Jun 12, 2023 / Business Wire / AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced the closing of the previously announced agreement to sell its investigational hematopoietic stem cell (HSC) gene... Read More

All-cash transaction, with full $87.5 million to be paid at closing Proceeds expected to extend cash runway into Q4 2024 CAMBRIDGE, Mass. / May 22, 2023 / Business Wire / AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced an agreement to sell its investigational hematopoietic stem cell (HSC) gene therapy program for the... Read More

All patients remain off oral cysteamine up to 36 months post gene therapy Sustained engraftment and durable reduction in leukocyte cystine levels across all patients Received positive regulatory feedback from US and UK agencies CAMBRIDGE, Mass. / May 18, 2023 / Business Wire / AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced... Read More

On track to initiate registrational global Phase 2/3 clinical trial for Gaucher disease type 3 (GD3) in second half 2023, subject to regulatory alignment Plan to provide clinical and regulatory updates on cystinosis program in conjunction with ASGCT annual meeting in May 2023; plan to initiate late-stage cystinosis clinical trial activities in second half 2023, subject to regulatory alignment Collaborator-sponsored Phase 1/2... Read More

Current CFO Erik Ostrowski named interim CEO, replacing Founding President and CEO Geoff MacKay CAMBRIDGE, Mass. / May 01, 2023 / Business Wire / AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced the appointment of Erik Ostrowski as interim Chief Executive Officer effective as of today. Mr. Ostrowski, who will continue as... Read More

Following positive regulatory feedback, plan to initiate registrational global Phase 2/3 clinical trial for Gaucher disease type 3 (GD3) in second half 2023, subject to regulatory alignment Patient dosing completed in collaborator-sponsored Phase 1/2 clinical trial for cystinosis; plan to initiate late-stage clinical trial activities in second half 2023, subject to regulatory alignment; expect to provide clinical and... Read More

CAMBRIDGE, Mass. / Mar 03, 2023 / Business Wire / AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in a panel titled “Orphan Neuro Corporate Panel” at Cowen’s 43 rd Annual Health Care Conference on Tuesday, March 7, 2023 at 10:30 AM ET at the Boston... Read More

CAMBRIDGE, Mass. / Feb 09, 2023 / Business Wire / AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that updated data suggesting complete biochemical correction in the first pediatric Gaucher disease type 3 (GD3) patient treated with hematopoietic stem cell (HSC) gene therapy, including improvements in major refractory... Read More

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 7,500 restricted stock units (RSUs) to one new employee as an inducement award under the company’s 2019 Inducement Plan. The grant was made in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs were granted on Jan. 3, 2023, as... Read More

New compelling clinical data from first-ever Gaucher disease type 3 (GD3) patient and four Gaucher disease type 1 (GD1) patients dosed with investigational AVR-RD-02 Data from first pediatric GD3 patient, the more severe, progressive form of Gaucher disease, show biochemical correction and improvement in major refractory element of disease 15 months post gene therapy Data from first four adult patients dosed in GD1 clinical... Read More